Snowden Capital Advisors’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-475
Closed -$20K 1510
2021
Q4
$20K Buy
+475
New +$22.5K ﹤0.01% 1330

Other funds holding IDNA

Snowden Capital Advisors's IDNA Position: Q1 2022 in Review

Snowden Capital Advisors sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q1 2022, closing a stake of 475 shares — an estimated $20K sold.

Snowden Capital Advisors first reported a position in IDNA in Q4 2021 and held it in 1 quarter. The position peaked at $20K in Q4 2021. 86 funds tracked by Wall St. Rank hold IDNA as of Q1 2022.

  • Snowden Capital Advisors reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 475 iShares Genomics Immunology and Healthcare ETF shares in Q1 2022, an estimated $20K.
  • Snowden Capital Advisors first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's iShares Genomics Immunology and Healthcare ETF position peaked at $20K in Q4 2021.
  • 86 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.